BR0308145A - Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto - Google Patents
Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um compostoInfo
- Publication number
- BR0308145A BR0308145A BR0308145-1A BR0308145A BR0308145A BR 0308145 A BR0308145 A BR 0308145A BR 0308145 A BR0308145 A BR 0308145A BR 0308145 A BR0308145 A BR 0308145A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hydroxy
- halo
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Amidas heterocíclicas da fórmula (1): em que: Z é CH ou nitrogênio; R^ 4^ e R^ 5^ juntos são ou -S-C(R^ 6^)=C(R^ 7^)- ou -C(R^ 7^)=C(R^ 6^)-S-; R^ 6^ e R^ 7^ são selecionados a partir, por exemplo, de hidrogênio, halo, alquila C~ 1-4~ e alcanoíla C~ 1-4~; A é fenileno ou heteroarileno; n é 0, 1 ou 2; R^ 1^ é selecionado, por exemplo, a partir de halo, nitro, ciano, hidróxi, carbóxi; r é 1 ou 2; Y é -NR^ 2^R^ 3^ ou - OR^ 3^; R^ 2^ e R^ 3^ são selecionados a partir de, por exemplo, hidrogênio, hidróxi, arila, heterociclila e alquila C~ 1-4~ (opcionalmente substituído por 1 ou 2 grupos R^ 8^); R^ 4^ é selecionado, por exemplo, a partir de hidrogênio, halo, nitro, ciano, hidróxi, alquila C~ 1-4~ e alcanoíla; R^ 8^ é selecionado, por exemplo, a partir de hidróxi, -COCOOR^ 9^,- C(O)N(R^ 9^)(R^ 10^), - NHC(O)R^ 9^, (R^ 9^) (R^ 10^)N- e -COOR^ 9^; R^ 9^ e R^ 10^ são selecionados, por exemplo, a partir de hidrogênio, hidróxi, alquila C~ 1-4~ (opcionalmente substituido por 1 ou 2 R^ 13^); R^ 13^ é selecionado a partir de hidróxi, halo, trifluorometila e alcóxi C~ 1-4~; ou um sal farmaceuticamente aceitável ou pró-droga dos mesmos; possuem atividade inibitória de glicogênio fosforilase e portanto possuem valor no tratamento de estados de doença associados com atividade de glicogênio fosforilase aumentada. Processos para a manufatura dos referidos derivados de amida heterocíclica e composições farmacêuticas contendo os mesmos são descritos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205170.4A GB0205170D0 (en) | 2002-03-06 | 2002-03-06 | Chemical compounds |
| PCT/GB2003/000875 WO2003074531A1 (en) | 2002-03-06 | 2003-03-04 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308145A true BR0308145A (pt) | 2004-12-07 |
Family
ID=9932334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308145-1A BR0308145A (pt) | 2002-03-06 | 2003-03-04 | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7122567B2 (pt) |
| EP (1) | EP1483271B1 (pt) |
| JP (1) | JP2005524669A (pt) |
| KR (1) | KR20040091101A (pt) |
| CN (1) | CN1307183C (pt) |
| AR (1) | AR038886A1 (pt) |
| AT (1) | ATE346072T1 (pt) |
| AU (1) | AU2003209445A1 (pt) |
| BR (1) | BR0308145A (pt) |
| CA (1) | CA2477125A1 (pt) |
| DE (1) | DE60309849T2 (pt) |
| DK (1) | DK1483271T3 (pt) |
| ES (1) | ES2276092T3 (pt) |
| GB (1) | GB0205170D0 (pt) |
| IL (1) | IL163802A0 (pt) |
| IS (1) | IS7433A (pt) |
| MX (1) | MXPA04008611A (pt) |
| NO (1) | NO20044033L (pt) |
| NZ (1) | NZ534684A (pt) |
| PL (1) | PL372772A1 (pt) |
| PT (1) | PT1483271E (pt) |
| RU (1) | RU2004125145A (pt) |
| TW (1) | TW200306176A (pt) |
| WO (1) | WO2003074531A1 (pt) |
| ZA (1) | ZA200406685B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| JP4630267B2 (ja) * | 2002-12-25 | 2011-02-09 | 第一三共株式会社 | ジアミン誘導体 |
| MXPA05006989A (es) * | 2002-12-25 | 2005-09-22 | Daiichi Seiyaku Co | Derivados de diamina. |
| GB0318463D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| CN1922149A (zh) | 2003-12-29 | 2007-02-28 | 塞普拉科公司 | 吡咯和吡唑daao抑制剂 |
| WO2006055462A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055463A2 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) * | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| TWI281231B (en) * | 2004-12-20 | 2007-05-11 | Hynix Semiconductor Inc | Method for forming storage node of capacitor in semiconductor device |
| EP1976513B1 (en) | 2006-01-06 | 2016-08-24 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| KR101381768B1 (ko) | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
| PT2816024T (pt) | 2006-03-31 | 2017-10-20 | Sunovion Pharmaceuticals Inc | Aminas quirais |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| WO2008151156A1 (en) | 2007-05-31 | 2008-12-11 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200740C (pt) | ||||
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4668769A (en) | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4599198A (en) | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4720503A (en) | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| JPH04179949A (ja) | 1990-11-15 | 1992-06-26 | Fuji Photo Film Co Ltd | 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料 |
| CA2137832C (en) | 1992-06-12 | 2000-09-26 | Dennis J. Hoover | Inhibitors of angiotensin i chymase(s) including human heart chymase |
| ES2081747B1 (es) * | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| AU1890295A (en) | 1994-03-09 | 1995-09-25 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| FR2723739B1 (fr) | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| DE4445968A1 (de) | 1994-12-22 | 1996-06-27 | Bayer Ag | Verwendung von Sulfonylguanazinen |
| ES2164151T3 (es) | 1995-06-06 | 2002-02-16 | Pfizer | N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa. |
| JP3314938B2 (ja) | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| FI974437A0 (fi) | 1995-06-06 | 1997-12-05 | Pfizer | Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina |
| EP1040827A3 (en) | 1995-09-08 | 2000-10-11 | Novo Nordisk A/S | Use of 2-alkylpyrrolidines for the treatment of diabetes |
| AU2090897A (en) | 1996-02-29 | 1997-09-16 | Mikael Bols | Hydroxyhexahydropyridazines |
| EP0914322A1 (en) | 1996-05-27 | 1999-05-12 | Fujisawa Pharmaceutical Co., Ltd. | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| WO1998027108A2 (en) | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| ZA981920B (en) | 1997-03-07 | 1998-09-07 | Novo Nordisk As | Novel heterocyclic compounds |
| WO1998050359A1 (en) | 1997-05-06 | 1998-11-12 | Novo Nordisk A/S | Novel heterocyclic compounds |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| ATE494388T1 (de) | 1999-01-13 | 2011-01-15 | Univ New York State Res Found | Neues verfahren zum erschaffen von proteinkinase- inhibitoren |
| AU2535700A (en) | 1999-02-12 | 2000-08-29 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
| US6043091A (en) | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| WO2001023347A1 (en) | 1999-09-29 | 2001-04-05 | Novo Nordisk A/S | Novel aromatic compounds |
| DE60007592T2 (de) * | 1999-09-30 | 2004-09-16 | Pfizer Products Inc., Groton | Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| RU2260009C2 (ru) | 1999-11-05 | 2005-09-10 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) | Новые гетероциклические соединения и их применение в качестве лекарственных средств |
| DK1248604T4 (da) | 2000-01-21 | 2012-05-21 | Novartis Ag | Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| UY26615A1 (es) | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| ATE266409T1 (de) | 2000-04-13 | 2004-05-15 | Pfizer Prod Inc | Synergistische wirkung von glyburide und milrinone |
| EP1294682B1 (de) | 2000-06-09 | 2004-04-28 | Aventis Pharma Deutschland GmbH | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| AU2001288110A1 (en) | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| EP1338594A4 (en) | 2000-11-01 | 2004-06-16 | Shionogi & Co | PGD2 RECEPTOR ANTAGONIST PHARMACEUTICAL COMPOSITIONS |
| US20030147866A1 (en) | 2001-04-04 | 2003-08-07 | Nicolette Charles A. | Novel BGP compounds for therapy and diagnosis and methods for using same |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| JP2005506956A (ja) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | 長時間作用性ｇｌｐ−１製剤 |
| EP1452526A1 (en) | 2001-10-29 | 2004-09-01 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
| EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| JPWO2003091213A1 (ja) | 2002-04-25 | 2005-09-02 | アステラス製薬株式会社 | 新規なアミド誘導体又はその塩 |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| JP2006507294A (ja) | 2002-11-07 | 2006-03-02 | ファイザー・プロダクツ・インク | 抗糖尿病剤 |
| US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| US7501440B2 (en) * | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| EP1620427A1 (en) | 2003-04-17 | 2006-02-01 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
| EP1633709A1 (en) * | 2003-04-30 | 2006-03-15 | Pfizer Products Inc. | Anti-diabetic agents |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020986A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| WO2005020985A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-03-06 GB GBGB0205170.4A patent/GB0205170D0/en not_active Ceased
-
2003
- 2003-03-04 CA CA002477125A patent/CA2477125A1/en not_active Abandoned
- 2003-03-04 US US10/506,746 patent/US7122567B2/en not_active Expired - Fee Related
- 2003-03-04 MX MXPA04008611A patent/MXPA04008611A/es active IP Right Grant
- 2003-03-04 CN CNB038051249A patent/CN1307183C/zh not_active Expired - Fee Related
- 2003-03-04 IL IL16380203A patent/IL163802A0/xx unknown
- 2003-03-04 DE DE60309849T patent/DE60309849T2/de not_active Expired - Fee Related
- 2003-03-04 PL PL03372772A patent/PL372772A1/xx not_active Application Discontinuation
- 2003-03-04 ES ES03743418T patent/ES2276092T3/es not_active Expired - Lifetime
- 2003-03-04 KR KR10-2004-7013865A patent/KR20040091101A/ko not_active Ceased
- 2003-03-04 BR BR0308145-1A patent/BR0308145A/pt not_active IP Right Cessation
- 2003-03-04 EP EP03743418A patent/EP1483271B1/en not_active Expired - Lifetime
- 2003-03-04 AU AU2003209445A patent/AU2003209445A1/en not_active Abandoned
- 2003-03-04 WO PCT/GB2003/000875 patent/WO2003074531A1/en not_active Ceased
- 2003-03-04 NZ NZ534684A patent/NZ534684A/en unknown
- 2003-03-04 PT PT03743418T patent/PT1483271E/pt unknown
- 2003-03-04 AT AT03743418T patent/ATE346072T1/de not_active IP Right Cessation
- 2003-03-04 RU RU2004125145/04A patent/RU2004125145A/ru not_active Application Discontinuation
- 2003-03-04 DK DK03743418T patent/DK1483271T3/da active
- 2003-03-04 JP JP2003572999A patent/JP2005524669A/ja not_active Withdrawn
- 2003-03-05 TW TW092104655A patent/TW200306176A/zh unknown
- 2003-03-06 AR ARP030100766A patent/AR038886A1/es unknown
-
2004
- 2004-08-23 ZA ZA200406685A patent/ZA200406685B/en unknown
- 2004-09-01 IS IS7433A patent/IS7433A/is unknown
- 2004-09-24 NO NO20044033A patent/NO20044033L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003074531A1 (en) | 2003-09-12 |
| US20050131052A1 (en) | 2005-06-16 |
| AR038886A1 (es) | 2005-02-02 |
| AU2003209445A1 (en) | 2003-09-16 |
| ZA200406685B (en) | 2005-10-31 |
| CN1639167A (zh) | 2005-07-13 |
| IS7433A (is) | 2004-09-01 |
| DK1483271T3 (da) | 2007-02-19 |
| EP1483271B1 (en) | 2006-11-22 |
| PT1483271E (pt) | 2007-02-28 |
| HK1070365A1 (en) | 2005-06-17 |
| DE60309849T2 (de) | 2007-06-14 |
| ATE346072T1 (de) | 2006-12-15 |
| CA2477125A1 (en) | 2003-09-12 |
| NO20044033L (no) | 2004-11-25 |
| GB0205170D0 (en) | 2002-04-17 |
| EP1483271A1 (en) | 2004-12-08 |
| RU2004125145A (ru) | 2005-06-10 |
| DE60309849D1 (de) | 2007-01-04 |
| IL163802A0 (en) | 2005-12-18 |
| ES2276092T3 (es) | 2007-06-16 |
| CN1307183C (zh) | 2007-03-28 |
| KR20040091101A (ko) | 2004-10-27 |
| PL372772A1 (en) | 2005-08-08 |
| JP2005524669A (ja) | 2005-08-18 |
| TW200306176A (en) | 2003-11-16 |
| US7122567B2 (en) | 2006-10-17 |
| NZ534684A (en) | 2006-02-24 |
| MXPA04008611A (es) | 2004-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308146A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
| ATE126216T1 (de) | Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung. | |
| BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
| BR0214989A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto | |
| BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| ATE212991T1 (de) | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften | |
| BRPI0413233A (pt) | novos compostos | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
| BR9911013A (pt) | Derivados de pirazol como inibidores da p-38 map quinase | |
| BRPI0309534B8 (pt) | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica | |
| BR9910467A (pt) | Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida | |
| ES2161418T3 (es) | Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos. | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| HUP0303281A2 (hu) | Benzodiazepinszármazékok, mint GABA A receptor modulátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |